Christof Specker

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/8380111/christof-specker-publications-by-year.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

46 2,510 30 79 g-index h-index citations papers 4.79 134 3,394 3.1 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
79	TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD. <i>RMD Open</i> , 2021 , 7, e001896	5.9	4
78	TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD. <i>RMD Open</i> , 2021 , 7,	5.9	2
77	The influence of the SARS-CoV-2 lockdown on patients with inflammatory rheumatic diseases on their adherence to immunomodulatory medication: a cross sectional study over 3 months in Germany. <i>Rheumatology</i> , 2021 , 60, SI51-SI58	3.9	4
76	Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1137-1146	2.4	49
75	Safety management in treatment with antimalarials in rheumatology. Interdisciplinary recommendations on the basis of aßystematic literature review. <i>Zeitschrift Fur Rheumatologie</i> , 2021 , 80, 1-9	1.9	13
74	Mission statement from rheumatologists in the German Society of Rheumatology (DGRh e. V.): We live rheumatology. <i>Zeitschrift Fur Rheumatologie</i> , 2021 , 80, 10-12	1.9	0
73	Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. <i>RMD Open</i> , 2021 , 7,	5.9	33
72	Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in times of SARS-CoV-2-methodology, key messages and justifying information. <i>Rheumatology</i> , 2021 , 60, 2128-2133	3.9	7
71	Vaccination of patients with inflammatory rheumatic diseases against SARS-CoV-2: considerations before widespread availability of the vaccines. <i>RMD Open</i> , 2021 , 7,	5.9	17
70	A survey to evaluate knowledge, perceptions and attitudes toward COVID-19 vaccinations among rheumatologists in Germany. <i>Rheumatology International</i> , 2021 , 41, 1949-1956	3.6	2
69	Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2/COVID-19 pandemic, including recommendations for COVID-19 vaccination. <i>Zeitschrift Fur Rheumatologie</i> , 2021 , 1	1.9	1
68	ICHIBAN, a non-interventional study evaluating tocilizumab long-term effectiveness and safety in patients with active rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 319-328	2.2	1
67	Preliminary recommendations of the German Society of Rheumatology (DGRh eV) for the management of patients with inflammatory rheumatic diseases during the SARS-CoV-2/COVID-19 pandemic. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 840-842	2.4	28
66	Canakinumab for Treatment of Adult-Onset Stills Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1090-1097	2.4	32
65	Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial. <i>Lancet, The</i> , 2020 , 396, 267-276	40	20
64	National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD. <i>RMD Open</i> , 2020 , 6,	5.9	26
63	No advice to discontinue antirheumatic therapy for non-medical reasons in light of SARS-CoV-2. Response to: ¶reatment adherence of patients with sytemic rheumatic diseases in COVID-19 pandemicSby Fragoulis. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	3

(2013-2019)

62	Erythematosus Is Associated with Active Disease. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	11
61	The German National Registry of Primary Immunodeficiencies (2012-2017). <i>Frontiers in Immunology</i> , 2019 , 10, 1272	8.4	40
60	IL-22 production of effector CD4 T-cells is altered in SLE patients. <i>European Journal of Medical Research</i> , 2019 , 24, 24	4.8	5
59	Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	48
58	Nailfold Capillaroscopy Characteristics of Antisynthetase Syndrome and Possible Clinical Associations: Results of a Multicenter International Study. <i>Journal of Rheumatology</i> , 2019 , 46, 279-284	4.1	25
57	Swimming against the stream: the fishbowl discussion method as an interactive tool for medical conferences: experiences from the 11th European Lupus Meeting. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 713-714	2.4	2
56	Timing of onset affects arthritis presentation pattern in antisyntethase syndrome. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36, 44-49	2.2	29
55	Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group. <i>Clinical Reviews in Allergy and Immunology</i> , 2017 , 52, 71-80	12.3	48
54	Pregnancy in systemic lupus erythematosus and antiphospholipid syndrome. <i>Best Practice and Research in Clinical Rheumatology</i> , 2017 , 31, 397-414	5.3	42
	Cardiovascular Comorbidity in Inflammatory Rheumatological Conditions. <i>Deutsches</i>		
53	Ärzteblatt International, 2017 , 114, 197-203	2.5	21
53 52		2.5	21
	Ärzteblatt International, 2017 , 114, 197-203	2.5 4·4	21
52	Ärzteblatt International, 2017, 114, 197-203 Rheumatologie 2017, 469-497 First Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of Systemic Lupus Erythematosus in Germany: Results from the OBSErve Germany Study. Rheumatology and		
52 51	Ärzteblatt International, 2017, 114, 197-203 Rheumatologie 2017, 469-497 First Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of Systemic Lupus Erythematosus in Germany: Results from the OBSErve Germany Study. Rheumatology and Therapy, 2016, 3, 271-290	4.4	
52 51 50	Ärzteblatt International, 2017, 114, 197-203 Rheumatologie 2017, 469-497 First Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of Systemic Lupus Erythematosus in Germany: Results from the OBSErve Germany Study. Rheumatology and Therapy, 2016, 3, 271-290 Overlap-Syndrome. Aktuelle Rheumatologie, 2016, 41, 76-80 Clinical Spectrum Time Course in Anti Jo-1 Positive Antisynthetase Syndrome: Results From an	4.4	44
52 51 50 49	Rheumatologie 2017, 469-497 First Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of Systemic Lupus Erythematosus in Germany: Results from the OBSErve Germany Study. Rheumatology and Therapy, 2016, 3, 271-290 Overlap-Syndrome. Aktuelle Rheumatologie, 2016, 41, 76-80 Clinical Spectrum Time Course in Anti Jo-1 Positive Antisynthetase Syndrome: Results From an International Retrospective Multicenter Study. Medicine (United States), 2015, 94, e1144 Increased percentages of PD-1 on CD4+ T cells is associated with higher INF-[production and altered IL-17 production in patients with systemic lupus erythematosus. Scandinavian Journal of	4·4 0.1 1.8	44 91
52 51 50 49 48	Rheumatologie 2017, 469-497 First Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of Systemic Lupus Erythematosus in Germany: Results from the OBSErve Germany Study. Rheumatology and Therapy, 2016, 3, 271-290 Overlap-Syndrome. Aktuelle Rheumatologie, 2016, 41, 76-80 Clinical Spectrum Time Course in Anti Jo-1 Positive Antisynthetase Syndrome: Results From an International Retrospective Multicenter Study. Medicine (United States), 2015, 94, e1144 Increased percentages of PD-1 on CD4+ T cells is associated with higher INF-[production and altered IL-17 production in patients with systemic lupus erythematosus. Scandinavian Journal of Rheumatology, 2014, 43, 307-13 German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional	4.4 0.1 1.8	449123

44	Vergleich der Therapie-Compliance durch Befragung von RA-Patienten unter Infusionstherapie mit Rituximab und subkutan verabreichten TNFBlockern. <i>Aktuelle Rheumatologie</i> , 2013 , 38, 119-122	0.1	
43	Low risk of renal flares and negative outcomes in women with lupus nephritis conceiving after switching from mycophenolate mofetil to azathioprine. <i>Rheumatology</i> , 2013 , 52, 1070-6	3.9	52
42	Arthroscopic synovectomy and radiosynoviorthesis: a treatment option for recurrent arthritis symptoms in patients with pachydermoperiostosis. <i>Reumatismo</i> , 2013 , 65, 82-5	1.1	7
41	Synovitis and bone inflammation in early rheumatoid arthritis: high-resolution multi-pinhole SPECT versus MRI. <i>Diagnostic and Interventional Radiology</i> , 2013 , 19, 20-4	3.2	12
40	Mutations in the prostaglandin transporter encoding gene SLCO2A1 cause primary hypertrophic osteoarthropathy and isolated digital clubbing. <i>Human Mutation</i> , 2012 , 33, 660-4	4.7	59
39	Molecular imaging of cartilage damage of finger joints in early rheumatoid arthritis with delayed gadolinium-enhanced magnetic resonance imaging. <i>Arthritis and Rheumatism</i> , 2012 , 64, 394-9		37
38	Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID). <i>Journal of Rheumatology</i> , 2012 , 39, 2153-6	4.1	25
37	Current state of evidence on Soff-labelStherapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerlanda consensus report. <i>Lupus</i> , 2012 , 21, 386-401	2.6	51
36	Pregnancy outcome in patients with antiphospholipid syndrome after cerebral ischaemic events: an observational study. <i>Lupus</i> , 2012 , 21, 1183-9	2.6	39
35	Aberrant expression of the negative costimulator PD-1 on T cells in granulomatosis with polyangiitis. <i>Rheumatology</i> , 2012 , 51, 1188-97	3.9	43
34	Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). <i>Arthritis Research and Therapy</i> , 2011 , 13, R75	5.7	136
33	An ask-the-expert service on a rheumatology web site: who were the users and what did they look for?. <i>Arthritis Care and Research</i> , 2011 , 63, 604-11	4.7	9
32	Systemischer Lupus erythematodes und Antiphospholipid-Syndrom. <i>Aktuelle Rheumatologie</i> , 2010 , 35, 24-32	0.1	O
31	Increased expression of costimulatory markers CD134 and CD80 on interleukin-17 producing T cells in patients with systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2010 , 12, R150	5.7	47
30	Aktualisiertes Therapieschema der Rheumatoiden Arthritis. Ergebnisse eines Konsensusprozesses deutscher Rheumatologen 2009. <i>Aktuelle Rheumatologie</i> , 2009 , 34, 234-239	0.1	4
29	CD4+CD25+ T-cell populations expressing CD134 and GITR are associated with disease activity in patients with Wegener's granulomatosis. <i>Nephrology Dialysis Transplantation</i> , 2009 , 24, 161-71	4.3	39
28	Hypogonadism in Wegener's granulomatosis. Scandinavian Journal of Rheumatology, 2008, 37, 365-9	1.9	6
27	Self-assessments of patients via Tablet PC in routine patient care: comparison with standardised paper questionnaires. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67, 1739-41	2.4	73

26	Peripheral circulating activated b-cell populations are associated with nephritis and disease activity in patients with systemic lupus erythematosus. <i>Scandinavian Journal of Immunology</i> , 2007 , 66, 584-90	3.4	21
25	Rituximab as a treatment option for refractory endogenous anterior uveitis. <i>Ophthalmic Research</i> , 2007 , 39, 184-6	2.9	47
24	Hereditary periodic fever with systemic amyloidosis: is hyper-IgD syndrome really a benign disease?. <i>American Journal of Kidney Diseases</i> , 2006 , 48, e41-5	7.4	21
23	CD134 expression on CD4+ T cells is associated with nephritis and disease activity in patients with systemic lupus erythematosus. <i>Clinical and Experimental Immunology</i> , 2006 , 145, 235-42	6.2	43
22	Antiphospholipid syndrome in cardiac surgery-an underestimated coagulation disorder?. <i>European Journal of Cardio-thoracic Surgery</i> , 2005 , 28, 133-7	3	20
21	Gynkologische und geburtshilfliche Probleme beim Sjären-Syndrom. <i>Aktuelle Rheumatologie</i> , 2005 , 30, 56-58	0.1	O
20	Health care and burden of illness in systemic lupus erythematosus compared to rheumatoid arthritis: results from the National Database of the German Collaborative Arthritis Centres. <i>Lupus</i> , 2004 , 13, 529-36	2.6	24
19	Angiologische Diagnostik in der Rheumatologie. Aktuelle Rheumatologie, 2003 , 28, 73-80	0.1	
18	Differential diagnosis of high serum creatine kinase levels in systemic lupus erythematosus. <i>Rheumatology International</i> , 2003 , 23, 319-23	3.6	8
17	Jaccouds arthropathy in systemic lupus erythematosus: differentiation of deforming and erosive patterns by magnetic resonance imaging. <i>Arthritis and Rheumatism</i> , 2003 , 48, 157-65		100
17 16		4.5	100
	patterns by magnetic resonance imaging. <i>Arthritis and Rheumatism</i> , 2003 , 48, 157-65 Methotrexate treatment for refractory subacute cutaneous lupus erythematosus. <i>Journal of the</i>	4.5	
16	patterns by magnetic resonance imaging. <i>Arthritis and Rheumatism</i> , 2003 , 48, 157-65 Methotrexate treatment for refractory subacute cutaneous lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , 2002 , 46, 600-3 Relapsing polychondritis in childhoodcase report and short review. <i>Rheumatology International</i> ,		45
16 15	patterns by magnetic resonance imaging. <i>Arthritis and Rheumatism</i> , 2003 , 48, 157-65 Methotrexate treatment for refractory subacute cutaneous lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , 2002 , 46, 600-3 Relapsing polychondritis in childhoodcase report and short review. <i>Rheumatology International</i> , 2000 , 19, 231-4 Cerebral microembolism, a disease marker for ischemic cerebrovascular events in the antiphospholipid syndrome of systemic lupus erythematosus?. <i>Acta Neurologica Scandinavica</i> , 1999 ,	3.6	45 23
16 15 14	patterns by magnetic resonance imaging. <i>Arthritis and Rheumatism</i> , 2003 , 48, 157-65 Methotrexate treatment for refractory subacute cutaneous lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , 2002 , 46, 600-3 Relapsing polychondritis in childhoodcase report and short review. <i>Rheumatology International</i> , 2000 , 19, 231-4 Cerebral microembolism, a disease marker for ischemic cerebrovascular events in the antiphospholipid syndrome of systemic lupus erythematosus?. <i>Acta Neurologica Scandinavica</i> , 1999 , 99, 356-61 RheumaNeta novel Internet-based rheumatology information network in Germany. <i>Rheumatology</i> ,	3.6	45 23 28
16 15 14	patterns by magnetic resonance imaging. <i>Arthritis and Rheumatism</i> , 2003, 48, 157-65 Methotrexate treatment for refractory subacute cutaneous lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , 2002, 46, 600-3 Relapsing polychondritis in childhoodcase report and short review. <i>Rheumatology International</i> , 2000, 19, 231-4 Cerebral microembolism, a disease marker for ischemic cerebrovascular events in the antiphospholipid syndrome of systemic lupus erythematosus?. <i>Acta Neurologica Scandinavica</i> , 1999, 99, 356-61 RheumaNeta novel Internet-based rheumatology information network in Germany. <i>Rheumatology</i> , 1998, 37, 1015-9 Detection of cerebral microemboli in APSintroducing a novel investigation method and	3.6 3.8 3.9	45 23 28 7
16 15 14 13 12	methotrexate treatment for refractory subacute cutaneous lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , 2002 , 46, 600-3 Relapsing polychondritis in childhoodcase report and short review. <i>Rheumatology International</i> , 2000 , 19, 231-4 Cerebral microembolism, a disease marker for ischemic cerebrovascular events in the antiphospholipid syndrome of systemic lupus erythematosus?. <i>Acta Neurologica Scandinavica</i> , 1999 , 99, 356-61 RheumaNeta novel Internet-based rheumatology information network in Germany. <i>Rheumatology</i> , 1998 , 37, 1015-9 Detection of cerebral microemboli in APSintroducing a novel investigation method and implications of analogies with carotid artery disease. <i>Lupus</i> , 1998 , 7 Suppl 2, S75-80 High levels of circulating early apoptic peripheral blood mononuclear cells in systemic lupus	3.6 3.8 3.9 2.6	45 23 28 7

8	Significance of antibodies to cardiolipin in unselected patients with systemic lupus erythematosus: clinical and laboratory associations. The SLE Study Group. <i>Rheumatology International</i> , 1995 , 15, 23-9	3.6	29
7	Cerebral microembolism in patients with Sneddon's syndrome. <i>Archives of Neurology</i> , 1995 , 52, 271-5		39
6	Antiphospholipid antibodies in systemic lupus erythematosus and Sneddon's syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 1994 , 20, 55-63	5.3	14
5	HLA class II genes and antibodies against recombinant U1-nRNP proteins in patients with systemic lupus erythematosus. SLE Study Group. <i>Rheumatology International</i> , 1994 , 14, 63-9	3.6	7
4	Antiphospholipid syndrome complicating chronic graft-versus-host disease after allogeneic bone marrow transplantation. <i>American Journal of Hematology</i> , 1994 , 47, 143-4	7.1	13
3	Glucocorticoid receptors in rheumatoid arthritis. Arthritis and Rheumatism, 1992, 35, 740-4		90
2	Immunoglobulin allotypes are not associated with HLA-antigens, autoantibodies and clinical symptoms in systemic lupus erythematosus. Members of the SLE Study Group. <i>Rheumatology International</i> , 1991 , 11, 179-82	3.6	4
1	Immunoglobulin allotypes in systemic lupus erythematosusresults of a central European multicenter study. SLE Study Group. <i>Experimental and Clinical Immunogenetics</i> , 1991 , 8, 11-5		5